Global Injectable PrEP market size is predicted to grow from US$ 301 million in 2025 to US$ 831 million in 2032; it is expected to grow at a CAGR of 15.8% from 2026 to 2032.

Global Injectable PrEP Market Trends, Growth | CAGR Of 15.8%

The global Injectable PrEP market size is predicted to grow from US$ 301 million in 2025 to US$ 831 million in 2032; it is expected to grow at a CAGR of 15.8% from 2026 to 2032. Injectable PrEP refers to HIV pre-exposure prophylaxis administered via parenteral routes?typically intramuscular or subcutaneous injection?most often in long-acting formulations that create a sustained-release ?depot? and maintain protective drug exposure for weeks to months before potential HIV exposure occurs. The core problem it is designed to solve is the real-world implementation gap of oral PrEP: daily or event-driven pill-taking can be difficult to sustain due to adherence burden, refill continuity, privacy constraints, and stigma associated with visible medication use, and missed doses or interruptions can translate into gaps in protection. By shifting prevention from frequent self-managed dosing to periodic clinic- or program-based administration, injectable PrEP aims to improve continuity of coverage, reduce day-to-day behavioral load, and integrate more naturally with testing, follow-up, and broader sexual health services. Historically, injectable PrEP emerged after oral PrEP established efficacy and guidelines, leveraging advances from long-acting HIV treatment technologies?such as micro-/nano-crystal suspensions, stable depot formulations, and aseptic fill-finish?before expanding through regulatory approvals and phased rollout across regions, with service delivery models (visit cadence, workforce training, cold chain, and retention-in-care) becoming a central determinant of real-world uptake. Upstream, injectable PrEP depends on both conventional pharmaceutical inputs and a component-intensive aseptic supply chain: APIs and key intermediates; chemical reagents, solvents, and catalysts; injection-grade excipients (stabilizers, surfactants, buffers, water for injection, and formulation aids as needed); and the packaging/device components required for sterile manufacturing and administration (injectable-grade glass vials or prefilled syringes, elastomer stoppers/plungers, seals, needles and safety injection devices, sterilizing filters, single-use tubing and filling sets, labels, and cold-chain packaging), supported by specialized suppliers providing aseptic fill-finish capacity, sterilization validation, temperature-controlled logistics, and compliant quality systems.In 2025, the global production capacity of injectable PrEP reached 150,000 doses, while total sales amounted to 115,700 doses. The average selling price was USD 2,660 per dose, and manufacturers? gross margins ranged between 60% and 70%. United States market for Injectable PrEP is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032. China market for Injectable PrEP is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032. Europe market for Injectable PrEP is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032. Global key Injectable PrEP players cover Gilead Sciences, ViiV Healthcare, Aurobindo, Cipla, Viatris, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025. Infinity Market Research newest research report, the ?Injectable PrEP Industry Forecast? looks at past sales and reviews total world Injectable PrEP sales in 2025, providing a comprehensive analysis by region and market sector of projected Injectable PrEP sales for 2026 through 2032. With Injectable PrEP sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Injectable PrEP industry. This Insight Report provides a comprehensive analysis of the global Injectable PrEP landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Injectable PrEP portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Injectable PrEP market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Injectable PrEP and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Injectable PrEP. This report presents a comprehensive overview, market shares, and growth opportunities of Injectable PrEP market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Cabotegravir &nbsp;&nbsp;&nbsp; Lenacapavir &nbsp;&nbsp;&nbsp; Other &nbsp;&nbsp;&nbsp; Segmentation by Dosing Interval: &nbsp;&nbsp;&nbsp; Short-interval Injections &nbsp;&nbsp;&nbsp; Monthly Injections &nbsp;&nbsp;&nbsp; Quarterly Injections &nbsp;&nbsp;&nbsp; Segmentation by Drug Properties: &nbsp;&nbsp;&nbsp; Original Drug &nbsp;&nbsp;&nbsp; Generic Drug Segmentation by Application: &nbsp;&nbsp;&nbsp; Hospital &nbsp;&nbsp;&nbsp; Clinic &nbsp;&nbsp;&nbsp; Other This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Gilead Sciences &nbsp;&nbsp;&nbsp; ViiV Healthcare &nbsp;&nbsp;&nbsp; Aurobindo &nbsp;&nbsp;&nbsp; Cipla &nbsp;&nbsp;&nbsp; Viatris Key Questions Addressed in this Report What is the 10-year outlook for the global Injectable PrEP market? What factors are driving Injectable PrEP market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Injectable PrEP market opportunities vary by end market size? How does Injectable PrEP break out by Type, by Application?

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Injectable PrEP Annual Sales 2021-2032 &nbsp;2.1.2 World Current & Future Analysis for Injectable PrEP by Geographic Region, 2021, 2025 & 2032 &nbsp;2.1.3 World Current & Future Analysis for Injectable PrEP by Country/Region, 2021, 2025 & 2032 &nbsp;2.2 Injectable PrEP Segment by Type &nbsp;2.2.1 Cabotegravir &nbsp;2.2.2 Lenacapavir &nbsp;2.2.3 Other &nbsp;2.2.4 Injectable PrEP Sales by Type &nbsp;2.2.4.1 Global Injectable PrEP Sales Market Share by Type (2021-2026) &nbsp;2.2.4.2 Global Injectable PrEP Revenue and Market Share by Type (2021-2026) &nbsp;2.2.4.3 Global Injectable PrEP Sale Price by Type (2021-2026) &nbsp;2.3 Injectable PrEP Segment by Dosing Interval &nbsp;2.3.1 Short-interval Injections &nbsp;2.3.2 Monthly Injections &nbsp;2.3.3 Quarterly Injections &nbsp;2.3.4 Injectable PrEP Sales by Dosing Interval &nbsp;2.3.4.1 Global Injectable PrEP Sales Market Share by Dosing Interval (2021-2026) &nbsp;2.3.4.2 Global Injectable PrEP Revenue and Market Share by Dosing Interval (2021-2026) &nbsp;2.3.4.3 Global Injectable PrEP Sale Price by Dosing Interval (2021-2026) &nbsp;2.4 Injectable PrEP Segment by Drug Properties &nbsp;2.4.1 Original Drug &nbsp;2.4.2 Generic Drug &nbsp;2.4.3 Injectable PrEP Sales by Drug Properties &nbsp;2.4.3.1 Global Injectable PrEP Sales Market Share by Drug Properties (2021-2026) &nbsp;2.4.3.2 Global Injectable PrEP Revenue and Market Share by Drug Properties (2021-2026) &nbsp;2.4.3.3 Global Injectable PrEP Sale Price by Drug Properties (2021-2026) &nbsp;2.5 Injectable PrEP Segment by Application &nbsp;2.5.1 Hospital &nbsp;2.5.2 Clinic &nbsp;2.5.3 Other &nbsp;2.5.4 Injectable PrEP Sales by Application &nbsp;2.5.4.1 Global Injectable PrEP Sale Market Share by Application (2021-2026) &nbsp;2.5.4.2 Global Injectable PrEP Revenue and Market Share by Application (2021-2026) &nbsp;2.5.4.3 Global Injectable PrEP Sale Price by Application (2021-2026) 3 Global by Company &nbsp;3.1 Global Injectable PrEP Breakdown Data by Company &nbsp;3.1.1 Global Injectable PrEP Annual Sales by Company (2021-2026) &nbsp;3.1.2 Global Injectable PrEP Sales Market Share by Company (2021-2026) &nbsp;3.2 Global Injectable PrEP Annual Revenue by Company (2021-2026) &nbsp;3.2.1 Global Injectable PrEP Revenue by Company (2021-2026) &nbsp;3.2.2 Global Injectable PrEP Revenue Market Share by Company (2021-2026) &nbsp;3.3 Global Injectable PrEP Sale Price by Company &nbsp;3.4 Key Manufacturers Injectable PrEP Producing Area Distribution, Sales Area, Product Type &nbsp;3.4.1 Key Manufacturers Injectable PrEP Product Location Distribution &nbsp;3.4.2 Players Injectable PrEP Products Offered &nbsp;3.5 Market Concentration Rate Analysis &nbsp;3.5.1 Competition Landscape Analysis &nbsp;3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026) &nbsp;3.6 New Products and Potential Entrants &nbsp;3.7 Market M&A Activity & Strategy 4 World Historic Review for Injectable PrEP by Geographic Region &nbsp;4.1 World Historic Injectable PrEP Market Size by Geographic Region (2021-2026) &nbsp;4.1.1 Global Injectable PrEP Annual Sales by Geographic Region (2021-2026) &nbsp;4.1.2 Global Injectable PrEP Annual Revenue by Geographic Region (2021-2026) &nbsp;4.2 World Historic Injectable PrEP Market Size by Country/Region (2021-2026) &nbsp;4.2.1 Global Injectable PrEP Annual Sales by Country/Region (2021-2026) &nbsp;4.2.2 Global Injectable PrEP Annual Revenue by Country/Region (2021-2026) &nbsp;4.3 Americas Injectable PrEP Sales Growth &nbsp;4.4 APAC Injectable PrEP Sales Growth &nbsp;4.5 Europe Injectable PrEP Sales Growth &nbsp;4.6 Middle East & Africa Injectable PrEP Sales Growth 5 Americas &nbsp;5.1 Americas Injectable PrEP Sales by Country &nbsp;5.1.1 Americas Injectable PrEP Sales by Country (2021-2026) &nbsp;5.1.2 Americas Injectable PrEP Revenue by Country (2021-2026) &nbsp;5.2 Americas Injectable PrEP Sales by Type (2021-2026) &nbsp;5.3 Americas Injectable PrEP Sales by Application (2021-2026) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Injectable PrEP Sales by Region &nbsp;6.1.1 APAC Injectable PrEP Sales by Region (2021-2026) &nbsp;6.1.2 APAC Injectable PrEP Revenue by Region (2021-2026) &nbsp;6.2 APAC Injectable PrEP Sales by Type (2021-2026) &nbsp;6.3 APAC Injectable PrEP Sales by Application (2021-2026) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia &nbsp;6.10 China Taiwan 7 Europe &nbsp;7.1 Europe Injectable PrEP by Country &nbsp;7.1.1 Europe Injectable PrEP Sales by Country (2021-2026) &nbsp;7.1.2 Europe Injectable PrEP Revenue by Country (2021-2026) &nbsp;7.2 Europe Injectable PrEP Sales by Type (2021-2026) &nbsp;7.3 Europe Injectable PrEP Sales by Application (2021-2026) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Injectable PrEP by Country &nbsp;8.1.1 Middle East & Africa Injectable PrEP Sales by Country (2021-2026) &nbsp;8.1.2 Middle East & Africa Injectable PrEP Revenue by Country (2021-2026) &nbsp;8.2 Middle East & Africa Injectable PrEP Sales by Type (2021-2026) &nbsp;8.3 Middle East & Africa Injectable PrEP Sales by Application (2021-2026) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Manufacturing Cost Structure Analysis &nbsp;10.1 Raw Material and Suppliers &nbsp;10.2 Manufacturing Cost Structure Analysis of Injectable PrEP &nbsp;10.3 Manufacturing Process Analysis of Injectable PrEP &nbsp;10.4 Industry Chain Structure of Injectable PrEP 11 Marketing, Distributors and Customer &nbsp;11.1 Sales Channel &nbsp;11.1.1 Direct Channels &nbsp;11.1.2 Indirect Channels &nbsp;11.2 Injectable PrEP Distributors &nbsp;11.3 Injectable PrEP Customer 12 World Forecast Review for Injectable PrEP by Geographic Region &nbsp;12.1 Global Injectable PrEP Market Size Forecast by Region &nbsp;12.1.1 Global Injectable PrEP Forecast by Region (2027-2032) &nbsp;12.1.2 Global Injectable PrEP Annual Revenue Forecast by Region (2027-2032) &nbsp;12.2 Americas Forecast by Country (2027-2032) &nbsp;12.3 APAC Forecast by Region (2027-2032) &nbsp;12.4 Europe Forecast by Country (2027-2032) &nbsp;12.5 Middle East & Africa Forecast by Country (2027-2032) &nbsp;12.6 Global Injectable PrEP Forecast by Type (2027-2032) &nbsp;12.7 Global Injectable PrEP Forecast by Application (2027-2032) 13 Key Players Analysis &nbsp;13.1 Gilead Sciences &nbsp;13.1.1 Gilead Sciences Company Information &nbsp;13.1.2 Gilead Sciences Injectable PrEP Product Portfolios and Specifications &nbsp;13.1.3 Gilead Sciences Injectable PrEP Sales, Revenue, Price and Gross Margin (2021-2026) &nbsp;13.1.4 Gilead Sciences Main Business Overview &nbsp;13.1.5 Gilead Sciences Latest Developments &nbsp;13.2 ViiV Healthcare &nbsp;13.2.1 ViiV Healthcare Company Information &nbsp;13.2.2 ViiV Healthcare Injectable PrEP Product Portfolios and Specifications &nbsp;13.2.3 ViiV Healthcare Injectable PrEP Sales, Revenue, Price and Gross Margin (2021-2026) &nbsp;13.2.4 ViiV Healthcare Main Business Overview &nbsp;13.2.5 ViiV Healthcare Latest Developments &nbsp;13.3 Aurobindo &nbsp;13.3.1 Aurobindo Company Information &nbsp;13.3.2 Aurobindo Injectable PrEP Product Portfolios and Specifications &nbsp;13.3.3 Aurobindo Injectable PrEP Sales, Revenue, Price and Gross Margin (2021-2026) &nbsp;13.3.4 Aurobindo Main Business Overview &nbsp;13.3.5 Aurobindo Latest Developments &nbsp;13.4 Cipla &nbsp;13.4.1 Cipla Company Information &nbsp;13.4.2 Cipla Injectable PrEP Product Portfolios and Specifications &nbsp;13.4.3 Cipla Injectable PrEP Sales, Revenue, Price and Gross Margin (2021-2026) &nbsp;13.4.4 Cipla Main Business Overview &nbsp;13.4.5 Cipla Latest Developments &nbsp;13.5 Viatris &nbsp;13.5.1 Viatris Company Information &nbsp;13.5.2 Viatris Injectable PrEP Product Portfolios and Specifications &nbsp;13.5.3 Viatris Injectable PrEP Sales, Revenue, Price and Gross Margin (2021-2026) &nbsp;13.5.4 Viatris Main Business Overview &nbsp;13.5.5 Viatris Latest Developments 14 Research Findings and Conclusion

Report	Global Injectable PrEP Market Size, Share and Analysis Report 2026-2032
Selected License	Multi ID: ILR4847

Buyer Information

Order Summary